Reviewer's report

**Title:** Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs

**Version:** 1  **Date:** 7 November 2012

**Reviewer:** Akinori Yanaka

**Reviewer's report:**

Discretionary Revisions

1. Since the efficacy of PPI is influenced by genotype of CYP2C19, it seems also important to show the data on the adverse events of esomeprazole among three different genotypes of CYP2C19.

2. There are 5 cases of ulcer relapse, despite the treatment of esomeprazole for 1 year period. It seems useful to show clinical characteristic of the 5 cases by Table, in order to give us information about what kinds of risk factors are related to NSAIDs-related ulcer relapse among patients taking with esomeprazole.

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.